This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg
Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical
Industries, Ltd., and distributed by TEVA Pharmaceuticals USA with that of 5 mg/500 mg
METAGLIP™ Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500
mg tablet) in healthy adult subjects administered under fasting conditions.